Rare Disease Report

Clay Matthews Applauds Approval of Eteplirsen for Duchenne Muscular Dystrophy

SEPTEMBER 23, 2016
Clay Matthews

Clay Matthews from the Green Bay Packers is proud to support CureDuchenne in their mission to find a cure for Duchenne muscular dystrophy. The FDA granted accelerated approval to Sarepta for the first drug for Duchenne muscular dystrophy. CureDuchenne provided early funding to Sarepta that helped the company move into human clinical trials. We need to continue to advance treatments until there is a cure for all those with Duchenne. For more information go to www.CureDuchenne.org

Video provided courtesy of CureDuchenne.

Stay informed on the latest rare disease news and developments by signing up for our newsletter.
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.